Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170013/S013

Intraluminal Support Device LVIS/LVIS Jr./LVIS EVO

Microvention, Inc. · Decision date Sep 16, 2026

MEDTECHLEDGER EXPLANATIONP170013/S013

What did the FDA decide?

The FDA record shows a 30-day notice for P170013/S013, supplement reason listed as process change affecting manufacturer, sterilizer, packager or supplier. The stated purpose is to add automated robotic arms to the existing pickling and etching manufacturing processes for the LVIS/LVIS Jr./LVIS EVO intraluminal support device. The identifier ties this to PMA P170013, but the record is a supplement, not a new approval of the whole system, and it is a manufacturing notice rather than an original PMA.

The notice does not specify which manufacturing site is affected, the pickling or etching parameters involved, how the robotic arms integrate with existing steps, or what validation data were submitted. Nothing in the supplied fields reports safety or clinical effectiveness findings; the stated purpose of the change is distinct from proof of those outcomes.

The product is listed under product code QCA in the intracranial coil-assist stent category, with neurology as the specialty and MicroVention, Inc. as applicant.

FDA approval order statement

to add automated robotic arms to the existing pickling and etchingmanufacturing processes
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
Sep 16, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P170013/S013
Regulatory pathway
PMA supplement
Product code
QCA
Decision code
OK30
Decision date
Sep 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Intracranial coil-assist stent.

Product code
QCA
FDA device class
3

For the original device and its historical approval scope, see PMA P170013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P170013 · Original PMA

    Low-Profile Visualized Intraluminal Support (LVIS) and LVIS Jr.

  2. P170013/S013 received

    Application receipt date recorded by FDA.

  3. P170013/S013 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P170013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170013

Product / regulatory recordCompanyPathwayDecision dateSource
Microvention, Inc.PMA approvalMay 30, 2018FDA

Explore the linked device profile

Other records with product code QCA

Product / regulatory recordCompanyPathwayDecision dateSource
Stryker NeurovascularPMA supplementOct 24, 2026FDA
Stryker NeurovascularPMA approvalMay 16, 2019FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Microvention, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
35 Enterprise, Aliso Viejo, CA, 92656

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records